Viewing Study NCT00093314



Ignite Creation Date: 2024-05-05 @ 11:38 AM
Last Modification Date: 2024-10-26 @ 9:10 AM
Study NCT ID: NCT00093314
Status: WITHDRAWN
Last Update Posted: 2015-04-21
First Post: 2004-10-06

Brief Title: HuMax-CD20 in Chronic Lymphocytic Leukemia
Sponsor: GlaxoSmithKline
Organization: GlaxoSmithKline

Study Overview

Official Title: An Open-labeled International Multicenter Dose Escalating Phase III Trial of HuMax-CD20 a Fully Human Monoclonal Anti-CD20 Antibody in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status: WITHDRAWN
Status Verified Date: 2007-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Acquired asset
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this trial is to determine the safety and efficacy of HuMax-CD20 as a treatment for Chronic Lymphocytic Leukemia
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None